TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27411763
Drug: Cognitive-behavioral therapy-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy-based program for reducing internalized stigma, provided for 8 weeks (12 sessions)
Study: 22228560
Drug: SterolQ₁₀ (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SterolQ₁₀ (100 mg single dose)
Study: 22228560
Drug: generic CoQ₁₀
Approvals — FDA: no, EMA: no, PMDA: no
Description: generic CoQ₁₀ (100 mg single dose)
Study: 22228560
Drug: SterolQ₁₀ (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SterolQ₁₀ (100 mg/day for 4 weeks)
Study: 22228560
Drug: generic CoQ₁₀
Approvals — FDA: no, EMA: no, PMDA: no
Description: generic CoQ₁₀ (100 mg/day for 4 weeks)
Study: 20238367
Drug: Crestal approach
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crestal approach to lift the sinus lining with 8 mm implants
Study: 21594216
Drug: 5 mm
Normalized name: SUR-FIT 45 mm Wafer, Small
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mm short implants
Study: 10320178
Drug: Topical lidocaine-prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine-prilocaine cream (EMLA) applied transdermally for 3 hours before CT removal
Study: 10320178
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine administered 0.5 hours before CT removal
Study: 6127885
Drug: Prenalterol infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prenalterol infusion (5 micrograms/kg/min for 30 min)
Study: 6127885
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion (5 micrograms/kg/min for 30 min)
Study: 6127885
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (5 micrograms/kg/min for 30 min)
Study: 6127885
Drug: Prenalterol infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prenalterol infusion
Study: 27993193
Drug: Bilberries (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilberries (150 g, 3 times a week for 6 weeks)
Study: 27993193
Drug: Bilberries (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilberries (150 g, 3 times a week for 6 weeks) in men
Study: 17601896
Drug: Ceftriaxone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone plus azithromycin (1 g per week for 2 weeks)
Study: 17601896
Drug: Ceftriaxone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone plus doxycycline (200 mg/d for 2 weeks)
Study: 9579500
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (4 microg/kg)
Study: 9754085
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 5-fluorouracil (5-FU) and 70% glycolic acid (GA)
Study: 8151586
Drug: Bucillamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bucillamine (100 mg/day)
Study: 1747791
Drug: 5-Fluorouracil (5FU)
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-Fluorouracil (5FU) administered as a protracted venous infusion
Study: 30167975
Drug: Multiple exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple exercise therapy (training and stretching the knee and hip muscles)
Study: 30167975
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy (training the quadriceps muscles)
Study: 17824884
Drug: Topical dry
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dry mouth products containing olive oil, betaine, and xylitol
Study: 15922429
Drug: SWL plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SWL plus PDI therapy (median of four sessions, range 1 to 12)
Study: 9040453
Drug: Nitrendipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10 to 40 mg/d) with possible addition of enalapril (5 to 20 mg/d) and/or hydrochlorothiazide (12.5 to 25 mg/d)
Study: 3227054
Drug: High-dose haloperidol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose haloperidol (0.40 mg/kg)
Study: 3227054
Drug: Low-dose haloperidol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose haloperidol (0.15 mg/kg)
Study: 3227054
Drug: Test dose
Normalized name: Epinephrine/Lidocaine Hydrochloride Epidural Kit [ANESTHESIA TRAY (W/TEST DOSE)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test dose haloperidol (0.05 mg/kg)
Study: 16225528
Drug: Darifenacin 7.5
Normalized name: darifenacin 7.5 MG
DrugBank: Darifenacin (DB00496)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Darifenacin 7.5 mg once daily
Study: 16225528
Drug: Darifenacin 15
Normalized name: darifenacin 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin 15 mg once daily
Study: 16198072
Drug: Estradiol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (2 mg) and Norethisterone acetate (1 mg) daily for 6 months
Study: 2005294
Drug: Out-patient clinic
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Out-patient clinic treatment
Study: 29787859
Drug: Synbiotic (prebiotic:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic (prebiotic: fructooligosaccharides 4 g/day; probiotic: Bifidobacterium animalis subsp. lactis BB-12 at a minimum of 10 billion CFU/day)
Study: 25684233
Drug: Vanoxerine 200
Normalized name: Vanoxerine
DrugBank: Vanoxerine (DB03701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vanoxerine 200 mg
Study: 25684233
Drug: Vanoxerine 300
Normalized name: Vanoxerine
DrugBank: Vanoxerine (DB03701)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vanoxerine 300 mg
Study: 19038680
Drug: CRT-ON (Cardiac
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-ON (Cardiac Resynchronization Therapy)
Study: 506742
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg imipramine
Study: 506742
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg chlorimipramine
Study: 25886483
Drug: Mock transcutaneous
Normalized name: mockernut extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mock transcutaneous electrical nerve stimulation and sham intradermal acupuncture
Study: 19700936
Drug: Tulobuterol patch
Normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol patch (TP) at 2mg/day plus ICS
Study: 17760494
Drug: Morphine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (intravenous injection)
Study: 17760494
Drug: Codeine (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (intramuscular route)
Study: 11251433
Drug: Propofol target-concentration
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target-concentration infusion (4 mg.l‐1)
Study: 11251433
Drug: 8% sevoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% sevoflurane inhalation with 50% nitrous oxide
Study: 9758026
Drug: Continuous lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous lateral rotational therapy (CLRT) <40 degrees
Study: 8993096
Drug: Glycine (0.4-0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine (0.4-0.8 g/kg/day) added to neuroleptics
Study: 23683608
Drug: Acetazolamide (ACTZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACTZ) 500 mg administered intravenously to healthy subjects (HV)
Study: 23683608
Drug: Acetazolamide (ACTZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACTZ) 500 mg administered intravenously to peritoneal dialysis patients (CAPD)
Study: 16618980
Drug: nateglinide (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: nateglinide (270 mg/day)
Study: 16618980
Drug: voglibose (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: voglibose (0.6 mg/day)
Study: 1683365
Drug: High-flow face
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow face mask oxygen therapy (control)
Study: 7054205
Drug: 1.2 grams
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 grams of aspirin (low dose)
Study: 7054205
Drug: 3.6 grams
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 grams of aspirin (high dose)
Study: 22336473
Drug: Aspirin (100mg/day)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (100mg/day)
Study: 22718810
Drug: Olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg/day + Azelnidipine 16 mg/day
Study: 22718810
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg/day + Amlodipine 5 mg/day
Study: 8302071
Drug: 50 ml/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml/min
Study: 8302071
Drug: 75 ml/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 ml/min
Study: 8302071
Drug: 100 ml/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml/min
Study: 8302071
Drug: 200 ml/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml/min
Study: 8302071
Drug: 300 ml/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml/min
Study: 8302071
Drug: 500 ml/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml/min
Study: 8302071
Drug: Low flow
Normalized name: high mallow flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flow groups (50, 75, 100 ml/min)
Study: 8302071
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow groups (200, 300 ml/min)
Study: 3291548
Drug: Pressure reducing
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pressure reducing medical therapy
Study: 31774464
Drug: Ipilimumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (10 mg/kg)
Study: 31774464
Drug: Ipilimumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (3 mg/kg or 10 mg/kg)
Study: 28143504
Drug: Usual Treatment
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Treatment group (same information and counseling with limited interaction with the therapist)
Study: 18617536
Drug: Gastrectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrectomy plus chemotherapy
Study: 10689150
Drug: Intra-nasal live
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-nasal live attenuated influenza vaccine (Livac)
Study: 10689150
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccine (Ivac)
Study: 10689150
Drug: Baculovirus recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baculovirus recombinant vaccine or adjuvanted Ivac
Study: 9337824
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no long-term oxygen therapy)
Study: 2880596
Drug: Etintidine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etintidine 300 mg b.d.
Study: 2880596
Drug: Etintidine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etintidine 400 mg b.d.
Study: 2880596
Drug: Etintidine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etintidine 300 mg nocte.
Study: 2880596
Drug: Etintidine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etintidine 600 mg nocte.
Study: 2880596
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg nocte.
Study: 2880596
Drug: Etintidine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etintidine 300 mg b.d. and 400 mg b.d.
Study: 2880596
Drug: Etintidine (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etintidine (any dose) at bedtime.
Study: 17388755
Drug: Biphasic inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biphasic inhalation profiles with low flow segments of 300 mL to 900 mL inhaled volume at 8 L/min
Study: 17388755
Drug: Biphasic inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biphasic inhalation profiles
Study: 12042887
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment for 12 months
Study: 9527357
Drug: Chlorhexidine/thymol-containing varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine/thymol-containing varnish (Cervitec) applied twice within 3 days
Study: 2378441
Drug: Terbutaline (Bricanyl)
Normalized name: terbutaline sulfate Oral Solution [Bricanyl]
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbutaline (Bricanyl) 0.5 mg t.i.d. via Turbuhaler
Study: 2378441
Drug: Fenoterol (Berotec)
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (Berotec) 0.2 mg t.i.d. via Inhalator Ingelheim
Study: 1092727
Drug: Aspirin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3.6 Gm/day)
Study: 17938939
Drug: Cholestyramine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine with biofeedback therapy (group A)
Study: 17938939
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy alone (group B)
Study: 12620169
Drug: 1.5% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% lidocaine and 0.3% nifedipine applied twice daily for 6 weeks
Study: 8626984
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with Dermatophagoides extract
Study: 1370507
Drug: Detirelix 1
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Detirelix 1 mg
Study: 1370507
Drug: Detirelix 5
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Detirelix 5 mg
Study: 1370507
Drug: Detirelix 20
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Detirelix 20 mg
Study: 1370507
Drug: Detirelix 5
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Detirelix 5 mg and 20 mg
Study: 3383879
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (20 mg)
Study: 24281893
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Caffeine and Sodium Citrate
Study: 20702609
Drug: 75 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 μg I/d supplementation
Study: 20702609
Drug: 150 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 μg I/d supplementation
Study: 16583464
Drug: LD-rofecoxib (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LD-rofecoxib (0.3 mg/kg/day up to 12.5 mg/day)
Study: 16583464
Drug: HD-rofecoxib (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD-rofecoxib (0.6 mg/kg/day up to 25 mg/day)
Study: 16583464
Drug: naproxen (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen (15 mg/kg/day)
Study: 12664078
Drug: GLP‐2 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP‐2 infusion (25 pmol/kg body weight) for 4.5 hours
Study: 9169336
Drug: UVB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB plus calcipotriene 0.005% ointment twice daily
Study: 3886302
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mecillinam daily for 14 days
Study: 30554092
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids and vitamin E co-supplementation (1000 mg/day of omega-3 from flaxseed oil plus 400 IU/day of vitamin E)
Study: 29800375
Drug: Ketamine (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1-2 mg/kg IV bolus, then continuous infusion starting at 5 mcg/kg/min, titrated as needed)
Study: 22345630
Drug: Multimodal behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal behavioral treatment (MBT)
Study: 19929593
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch with concomitant memantine
Study: 19929593
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch without concomitant memantine
Study: 16263779
Drug: Intramuscular corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular corticosteroid injections (40 mg methylprednisolone acetate)
Study: 12883695
Drug: Fixed dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosing of epoetin alpha (10,000 IU)
Study: 12883695
Drug: Weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing of epoetin alpha (150 IU/kg)
Study: 2861282
Drug: Triazolam (TZ)
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triazolam (TZ) 0.5 to 3.0 mg
Study: 2861282
Drug: Pentobarbital (PTB)
Normalized name: Pentobarbital
DrugBank: Pentobarbital (DB00312)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentobarbital (PTB) 100 to 600 mg
Study: 10473885
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) therapy for 5 months
Study: 1929683
Drug: Hydrochlorothiazide (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (both doses)
Study: 7201757
Drug: Tobramycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (1 mg/kg)
Study: 7201757
Drug: Gentamicin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (1 mg/kg)
Study: 7201757
Drug: Cefazolin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (500 mg)
Study: 25559818
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of trastuzumab and lapatinib
Study: 28045953
Drug: Cyclophosphamide (CPM)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CPM) 750 mg/m2 body surface area
Study: 21198798
Drug: PCA cream
Normalized name: lauryl PCA
DrugBank: Pidolic acid (DB03088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA cream applied twice daily before UV irradiation
Study: 21198798
Drug: Control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cream applied twice daily before UV irradiation
Study: 21198798
Drug: PCA cream
Normalized name: lauryl PCA
DrugBank: Pidolic acid (DB03088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA cream applied after UV irradiation
Study: 21198798
Drug: Control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cream applied after UV irradiation
Study: 14689371
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 mg for the first two weeks, 80 mg for 5.5 months, and 40 mg for the last two weeks)
Study: 14689371
Drug: Metoprolol (47.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (47.5 mg for two weeks, 95 mg for 5.5 months, and 47.5 mg for the last two weeks)
Study: 10631628
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sumatriptan succinate alone
Study: 10631628
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sumatriptan succinate with 500 mg naproxen
Study: 9048267
Drug: β-Blockers (carvedilol
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-Blockers (carvedilol and bisoprolol)
Study: 9048267
Drug: Future studies
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Future studies (β-blocker Evaluation Survival Trial - BEST)
Study: 27391900
Drug: 9 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 9 months of intermittent anti-tuberculous therapy under DOTS (86 women)
Study: 21415777
Drug: Docetaxel and
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel and cisplatin (DP) chemotherapy
Study: 21415777
Drug: Mitomycin C,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin C, vindesine, and cisplatin (MVP) chemotherapy
Study: 12882671
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy with 50 mg mitomycin bound to 375 mg carbon adsorbent (MMC‐CH)
Study: 12882671
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (systemic chemotherapy 3 months after operation)
Study: 7995977
Drug: Alovudine at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alovudine at AUC12s of 50, 100, or 200 ng*h/mL for up to 16 weeks
Study: 3820493
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1500 mg/d)
Study: 27189323
Drug: S-1 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 80 mg/m2 twice daily plus nab-paclitaxel 220 mg/m2 on day 1
Study: 27189323
Drug: S-1 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 80 mg/m2 twice daily plus nab-paclitaxel 260 mg/m2 on day 1
Study: 27189323
Drug: S-1 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 and nab-paclitaxel combination therapy
Study: 21320109
Drug: Carisbamate 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carisbamate 1,200 mg/day
Study: 21320109
Drug: Combined carisbamate
Normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined carisbamate doses
Study: 21320109
Drug: Carisbamate 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carisbamate 1,200 mg
Study: 21320109
Drug: Carisbamate 800
Normalized name: Chlorphenesin Carbamate
DrugBank: Chlorphenesin carbamate (DB14656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carisbamate 800 mg
Study: 19276857
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g L-arginine before resistance exercise